This service focuses on early-stage drug discovery, offering a comprehensive platform for target identification, validation, hit-to-lead optimisation, and preclinical candidate selection. The service duration is adaptable, typically ranging from a few months to over a year, depending on the project stage and complexity. It is designed for pharmaceutical companies, biotech firms, and research institutions looking to accelerate their drug discovery efforts. The goal of the service is to identify promising therapeutic candidates through a combination of advanced screening technologies, assay development, and structure-activity relationship (SAR) studies. Key activities include high-throughput screening, lead identification, and optimisation, with ongoing support from a multidisciplinary team of in-house experts in medicinal chemistry, pharmacology, and bioinformatics. Expected outcomes include the delivery of optimised preclinical candidates, supported by robust data packages that facilitate a smooth transition into the next phases of drug development. Each project is tailored to meet specific client objectives, ensuring high-quality results and a clear path forward for further development.